Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: Cross-sectional postal questionnaire study

European Journal of Human Genetics

Volumn 20, Issue 7, 2012, Pages 722-728

  Huijgen, Roeland ^a   Homsma, Sietske J M ^a   Hutten, Barbara A ^a   Kindt, Iris ^b   Vissers, Maud N ^a   Kastelein, John J P ^a   Van Rijckevorsel, Jan L A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Foundation for the Identification of Persons with Inherited Hypercholesterolemia   (Netherlands)

Author keywords

Familial hypercholesterolemia; genetic testing; genetic testing and adverse effects; hyperlipoproteinemia Type II; life insurance

Indexed keywords

ADULT; ARTICLE; FAMILIAL DISEASE; FAMILIAL HYPERCHOLESTEROLAEMIA; FEMALE; GENETIC SCREENING; HEALTH CARE POLICY; HUMAN; HYPERCHOLESTEROLEMIA; INSURANCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADOLESCENT; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC TESTING; GENOME, HUMAN; GUIDELINES AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INSURANCE, LIFE; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; QUESTIONNAIRES; YOUNG ADULT;

EID: 84863728434     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2012.5     Document Type: Article

References (20)

1. Beaudet AL: Which way for genetic-test regulation? Leave test interpretation to specialists. Nature 2010; 466: 816-817.
2. Wilson JM, Jungner YG: Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968; 65: 281-393.
3. Goldstein JL, Hobbs HH, Brown MS: The Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill: New York, 2001.
4. Huijgen R, Vissers MN, Defesche JC, Lansberg PJ, Kastelein JJ, Hutten BA: Familial hypercholesterolemia: current treatment and advances in management. Expert Rev Cardiovasc Ther 2008; 6: 567-581.
5. Versmissen J, Oosterveer DM, Yazdanpanah M et al: Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.
6. Marang-van de Mheen PJ, van Maarle MC, Stouthard ME: Getting insurance after genetic screening on familial hypercholesterolaemia; the need to educate both insurers and the public to increase adherence to national guidelines in The Netherlands. J Epidemiol Community Health 2002; 56: 145-147. (Pubitemid 34098468)
7. Homsma SJ, Huijgen R, Middeldorp S, Sijbrands EJ, Kastelein JJ: Molecular screening for familial hypercholesterolaemia: consequences for life and disability insurance. Eur J Hum Genet 2008; 16: 14-17. (Pubitemid 350269234)
8. Sijbrands EJ, Tornij E, Homsma SJ: Mortality risk prediction by an insurance company and long-term follow-up of 62,000 men. PLoS ONE 2009; 4: e5457.
9. Rancourt E: Estimation with Nearest-Neighbour Imputation at Statistics Canada; in: American Statistical Association (ed): Proceedings of the Survey Research Methods Section, 1999, PP 131-138.
10. Neil HA, Mant D: Cholesterol screening and life assurance. BMJ 1991; 302: 891-893.
11. Neil HA, Hammond T, Mant D, Humphries SE: Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004; 328: 500-501. (Pubitemid 38293611)
12. Neil A, Cooper J, Betteridge J et al: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625-2633.
13. Slack J: Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 2: 1380-1382.
14. Umans-Eckenhausen MA, Sijbrands EJ, Kastelein JJ, Defesche JC: Low-density lipoprotein receptor gene mutations and cardiovascular risk in a large genetic cascade screening population. Circulation 2002; 106: 3031-3036. (Pubitemid 35440284)
15. Pijlman AH, Huijgen R, Verhagen SN et al: Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209: 189-194.
16. Huijgen R, Kindt I, Verhoeven SB et al: Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS ONE 2010; 5: e9220.
17. Phatak PD, Bonkovsky HL, Kowdley KV: Hereditary hemochromatosis: time for targeted screening. Ann Intern Med 2008; 149: 270-272.
18. Low L, King S, Wilkie T: Genetic discrimination in life insurance: empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom. BMJ 1998; 317: 1632-1635. (Pubitemid 28554548)
19. Josefson D: Clinton outlaws genetic discrimination in federal jobs. BMJ 2000; 320: 468.
20. Morrison PJ: Implications of genetic testing for insurance in the UK. Lancet 1998; 352: 1647-1648. (Pubitemid 28526121)